HBSP (USA)
-
Worldwide Niche Marketing (Spanish version)
Moriarty, Rowland T., Jr.; McQuade, KristaCase HBS-504S18MarketingDeals with the issue of niche marketing in a worldwide market. Barco Projection Systems makes video, data, and graphics projectors for the industrial market. They have traditionally been the performance leader. In August 1989, Sony Corp. introduced a higher performance graphics projector at a considerably lower price than Barco's existing projector. As a result, Barco is faced with being preempted in their fastest growing segment by a competitor ...Starting at €8.20
-
Paramount Equipment (Spanish version)
Baldwin, Carliss Y.; Wang, WeiCase HBS-916S14FinanceParamount Equipment, Inc., based in Fort Wayne, Indiana, is a large manufacturer of cranes and compact construction equipment, aerial work platforms, and food service equipment. Founded in 1987, Paramount now had manufacturing operations in 24 countries. However, it lost its competitive position because it took on too much debt in the form of bank borrowings relative to the risk level of its business. Now the company must seek funding and guarant...Starting at €8.20
-
Signode Industries, Inc. (A) (Spanish Version)
Moriarty, Rowland T., Jr.; May, David; Swartz, GordonCase HBS-502S10Marketingdivisión de envasado Signode Industries fabrica flejes de acero y plástico. En 1981, la compañía experimentó la mayor compra apalancada en la historia corporativa EE.UU.. El caso se centra en la necesidad de la división de envasado para mantener una alta rentabilidad en un mercado a la baja de flejes de acero. Desde 1974, ha ido perdiendo Signode 1% por año del mercado de flejes de acero. Desde entonces, ha habido también una erosión significativ...Starting at €8.20
-
Sistemas de proyección Barco (B)
Moriarty, Rowland T., Jr.; McQuade, KristaCase HBS-506S12MarketingActualizaciones Barco de proyección Sistemas (A).Starting at €5.74
-
Sistemas de proyección Barco (C)
Moriarty, Rowland T., Jr.; McQuade, KristaCase HBS-506S13MarketingActualizaciones Barco de proyección Sistemas (B).Starting at €5.74
-
Fortis Industries, Inc. (B) (Spanish Version)
Moriarty, Rowland T., Jr.; Swartz, GordonCase HBS-514S01MarketingDescribe si la empresa adopta la política de precios-flex discutido en el caso (A). aumento de precios en los flejes de metal materias primas se rescinde por la industria del acero.Starting at €5.74
-
Apple, Einhorn, y las iPrefs
Baldwin, Carliss Y.; Feit, Hanoch; Minasian, Edward A.; Van Buren, BrandonCase HBS-218S06FinanceEn marzo de 2013, Apple Inc. tiene un saldo de caja muy grande y está bajo presión para devolver efectivo a los accionistas. Hedge gestor de fondos David Einhorn cree que Apple puede "valor de desbloqueo" mediante la emisión de acciones preferentes perpetuas, apodado iPrefs. Henry Blodget, CEO de The Business Insider, no está de acuerdo, diciendo que "no se puede simplemente agitar su varita mágica y hacer algo de la nada." Este breve caso está d...Starting at €8.20
-
Fortis Industries, Inc. (A)
Moriarty, Rowland T., Jr.; May, David; Swartz, GordonCase HBS-511079-EMarketingFortis Industries' packaging division manufactures steel and plastic strapping. In 2007, the company underwent a leveraged buyout. The case focuses on the packaging division's need to maintain high profitability in a declining market for steel strapping. Since 1998, Fortis has been losing 1% per year of the steel strapping market. Since then, there has also been significant erosion of prices. The division president is faced with 1) decreasing pri...Starting at €8.20
-
Fortis Industries, Inc. (B)
Moriarty, Rowland T., Jr.; Swartz, GordonCase HBS-511080-EMarketingDescribes whether the company adopts the price-flex policy discussed in the (A) case. Price increase in steel strapping raw materials is rescinded by steel industry.Starting at €5.74
-
Roche's Acquisition of Genentech
Baldwin, Carliss Y.; Becker, Bo; Dessain, VincentCase HBS-210040-EFinanceFranz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly-owned shares of Roche's biotechnology subsidiary, Genentech. The case provides opportunities to analyze Roche's strategy with respect to Genentech, tStarting at €8.20